Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 3/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 2/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 2/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3275789 | 0.79 | TRPV6 (0.61) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL13476072 | 0.79 | ACHE (0.41) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL1804144 | 0.78 | ORAI1 (0.43) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL14135196 | 0.75 | LPL (0.41) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL219541 | 0.72 | ENPP2 (0.56) | MGLLENPP2 | |
| SCHEMBL2407138 | 0.69 | ENPP2 (0.35) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL3275709 | 0.68 | ORAI1 (0.38) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL3274666 | 0.68 | ORAI1 (0.38) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL2090551 | 0.67 | HSD17B1 (0.37) | — | |
| SCHEMBL2400576 | 0.66 | ENPP2 (0.32) | TRPV6ORAI1ORAI2ORAI3ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | claimed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | claimed |
| EP-1961756-A1 | NOVEL BISBORON COMPOUND | Japan Science and Technology Agency (JP) | 2008-08-27 | — | — | EP | claimed |
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1961756-A1 | NOVEL BISBORON COMPOUND | Japan Science and Technology Agency (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | TRPV6 61/4885ORAI1 58/4885ORAI2 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.